Glycine (Tablets) Instructions for Use
ATC Code
N07XX (Other drugs for the treatment of nervous system diseases)
Active Substance
Glycine (Rec.INN WHO registered)
Clinical-Pharmacological Group
A drug that improves brain metabolism
Pharmacotherapeutic Group
Other agents for the treatment of nervous system diseases
Pharmacological Action
An agent affecting brain metabolism, an essential amino acid. It is a central inhibitory neurotransmitter.
It improves metabolic processes in brain tissues and has a sedative and antidepressant effect.
It has glycinergic and GABA-ergic, α1-adrenoblocking, antioxidant, and antitoxic effects; regulates the activity of NMDA receptors and thereby reduces psychoemotional stress, aggressiveness, and conflict; improves social adaptation and mood, facilitates falling asleep, and normalizes sleep; increases mental performance; reduces the severity of vegetative-vascular disorders (including during menopause) and general cerebral disorders in ischemic stroke and traumatic brain injury, and the toxic effect of ethanol on the central nervous system.
It is effective as an auxiliary agent for epileptic seizures.
Pharmacokinetics
It easily penetrates most biological fluids and body tissues, including the brain.
It does not accumulate.
It is rapidly broken down in the liver by glycine oxidase to water and carbon dioxide.
Indications
As part of complex therapy: stress conditions, psychoemotional stress, reduced mental performance, behavioral disorders in children and adolescents, chronic alcoholism, interruption of binge drinking, the acute period of withdrawal syndrome, functional and organic lesions of the nervous system accompanied by increased excitability, emotional instability, decreased mental performance, and sleep disorders (including neuroses, neurosis-like states, encephalopathy of various origins, residual effects after brain and spinal cord injuries), ischemic stroke.
ICD codes
| ICD-10 code | Indication |
| F07 | Personality and behavioral disorders due to disease, damage or dysfunction of the brain |
| F10.2 | Chronic alcoholism |
| F10.3 | Withdrawal state |
| F43 | Reaction to severe stress and adjustment disorders |
| F48.0 | Neurasthenia |
| F48.9 | Unspecified neurotic disorder |
| F51.2 | Nonorganic disorders of the sleep-wake schedule |
| F90.0 | Disturbance of activity and attention |
| F91.9 | Conduct disorder, unspecified |
| G92 | Toxic encephalopathy |
| G93.4 | Unspecified encephalopathy |
| I63 | Cerebral infarction |
| I67.4 | Hypertensive encephalopathy |
| R45.1 | Restlessness and agitation |
| R45.8 | Other symptoms and signs involving emotional state (suicidal thoughts (tendencies)) |
| T90 | Sequelae of injuries of head |
| T91.3 | Sequelae of spinal cord injury |
| Z73.0 | Burn-out |
| Z73.3 | Stress, not elsewhere classified (physical and mental strain) |
| ICD-11 code | Indication |
| 6A05.Z | Attention deficit hyperactivity disorder, with unspecified presentation |
| 6A8Z | Affective disorders, unspecified |
| 6B4Z | Disorders specifically associated with stress, unspecified |
| 6B6Z | Dissociative disorders, unspecified |
| 6C40.2Z | Alcohol dependence, unspecified |
| 6C40.4Z | Alcohol withdrawal syndrome, unspecified |
| 6C40.Z | Disorders due to alcohol use, unspecified |
| 6C91.Z | Dissocial behavioral disorder, unspecified |
| 6E68 | Secondary emotionally labile personality disorder |
| 6E6Z | Unspecified secondary mental or behavioral syndromes |
| 7B2Z | Sleep-wake cycle disorders, unspecified |
| 8B11 | Cerebral ischemic stroke |
| 8B22.8 | Hypertensive encephalopathy |
| 8D43.0Y | Other specified toxic encephalopathy |
| 8D43.0Z | Toxic encephalopathy, unspecified |
| 8D44.Y | Other specified alcohol-related neurological disorders |
| 8E47 | Encephalopathy, not elsewhere classified |
| 8E4A.0 | Paraneoplastic or autoimmune disorders of the central nervous system, including brain and spinal cord |
| 8E63 | Post-cardiopulmonary bypass encephalopathy |
| MB22.0 | Abulia |
| MB24.F | Restlessness |
| MC4Y | Other specified symptoms or signs involving the ear or mastoid process |
| ME66.Y | Other specified skin changes |
| MF3Y | Other specified symptoms, signs, or clinical findings related to the female genital system |
| MG23 | Fear of death |
| MG24.00 | Fear of malignant neoplasm of digestive organs |
| MG24.01 | Fear of malignant neoplasm of breast |
| MG24.02 | Fear of malignant neoplasm of male genital organs |
| MG24.0Y | Other specified fear of cancer |
| MG24.0Z | Fear of cancer, unspecified |
| MG24.1 | Fear of human immunodeficiency virus |
| MG24.2 | Fear of hematological disease |
| MG24.3 | Fear of digestive system disease |
| MG24.4 | Fear of eye diseases |
| MG24.5 | Fear of heart disease |
| MG24.6 | Fear of hypertensive disease |
| MG24.7 | Fear of cardiovascular disease |
| MG24.8 | Fear of musculoskeletal disease |
| MG24.9 | Fear of neurological disease |
| MG24.A | Fear of respiratory disease |
| MG24.B | Fear of diseases of the endocrine system, nutritional disorders, or metabolic disorders |
| MG24.C | Fear of diseases of the urinary system |
| MG24.D | Fear of developing pregnancy complications |
| MG24.E | Fear of a sexually transmitted disease in women |
| MG24.F | Fear of a disease of the female genital organs or breast |
| MG24.G | Fear of a sexually transmitted disease in men |
| MG24.H | Fear of diseases of the male genital organs |
| MG24.Y | Other specified fear of disease |
| MG24.Z | Fear of disease, unspecified |
| NA0Z | Head injury, unspecified |
| NB2Z | Injury of nerves or spinal cord at thorax level, unspecified |
| NB6Z | Injury of spinal cord at abdomen, lower back and pelvis level, unspecified |
| ND36 | Other injuries involving multiple body regions, not elsewhere classified |
| ND51.Z | Unspecified injuries of spine and trunk at unspecified level |
| NF2Z | Unspecified injuries, poisonings or certain other consequences of external causes |
| QD85 | Burn-out |
| QE01 | Stress, not elsewhere classified |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Tablets
It is used sublingually or buccally.
For psychoemotional stress, decreased memory, attention, mental performance, mental retardation, deviant behavior, 100 mg is prescribed 2-3 times/day for 14-30 days.
For functional and organic lesions of the nervous system accompanied by increased excitability, emotional lability, and sleep disorders, children under 3 years are prescribed 50 mg per dose 2-3 times/day for 7-14 days, then 50 mg once/day for 7-10 days. The daily dose is 100-150 mg, the course dose is 2000-2600 mg. Children over 3 years and adults are prescribed 100 mg 2-3 times/day, the course of treatment is 7-14 days. The course of treatment can be increased to 30 days; if necessary, the course is repeated after 30 days.
For sleep disorders, 50-100 mg is prescribed 20 minutes before sleep or immediately before sleep (depending on age).
For ischemic cerebral stroke, 1000 mg is prescribed within the first 3-6 hours from the onset of the stroke, then 1000 mg/day for 1-5 days, then 50-100 mg 3 times/day for the next 30 days.
In narcology, it is used as a means to increase mental performance and reduce psychoemotional stress during remission in cases of encephalopathy, organic lesions of the central and peripheral nervous system, 100 mg 2-3 times/day for 14-30 days. If necessary, the courses are repeated 4-6 times a year.
Adverse Reactions
Possible allergic reactions.
Contraindications
Children under 3 years of age (for some dosage forms), hypersensitivity to glycine.
Use in Pregnancy and Lactation
Use during pregnancy and breastfeeding is not recommended.
Pediatric Use
Use in children is possible in appropriate dosage forms.
Geriatric Use
No restrictions on use are indicated.
Special Precautions
In patients prone to arterial hypotension, doses should be reduced and blood pressure should be monitored; if it decreases, glycine use should be discontinued.
Drug Interactions
It reduces the toxic effect of anticonvulsants, antipsychotics, and antidepressants.
When combined with hypnotics, tranquilizers, and neuroleptics, the central nervous system inhibitory effect is additive.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Over-the-Counter
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
Sublingual tablets 100 mg: 50 or 100 pcs.
Marketing Authorization Holder
Biotiki MNPK, LLC (Russia)
Dosage Form
 |
Glycine | Sublingual tablets 100 mg: 50 or 100 pcs. |
Dosage Form, Packaging, and Composition
Sublingual tablets white or almost white with marbled elements, round, flat-cylindrical, with a bevel and a score line.
| 1 tab. | |
| Glycine microencapsulated | 100 mg |
Excipients: methylcellulose – 1 mg, magnesium stearate – 1 mg.
50 pcs. – contour cell packs (1) – cardboard packs.
50 pcs. – contour cell packs (2) – cardboard packs.
Sublingual tablets 100 mg: 10, 20 or 50 pcs.
Marketing Authorization Holder
Vertex, JSC (Russia)
Dosage Form
|
Glycine | Sublingual tablets 100 mg: 10, 20 or 50 pcs. |
Dosage Form, Packaging, and Composition
Sublingual tablets white or almost white, round, flat-cylindrical in shape, with a bevel; marbling is allowed.
| 1 tab. | |
| Glycine | 100 mg |
Excipients: methylcellulose – 1.3 mg, magnesium stearate – 0.7 mg.
5 pcs. – cardboard contour cell packs (2) – cardboard packs.
10 pcs. – cardboard contour cell packs (1) – cardboard packs.
10 pcs. – cardboard contour cell packs (2) – cardboard packs.
10 pcs. – cardboard contour cell packs (5) – cardboard packs.
20 pcs. – cardboard contour cell packs (1) – cardboard packs.
10 pcs. – jars (1) – cardboard packs.
20 pcs. – jars (1) – cardboard packs.
50 pcs. – jars (1) – cardboard packs.
Sublingual tablets 100 mg: 50 pcs.
Marketing Authorization Holder
Ozon, LLC (Russia)
Dosage Form
|
Glycine | Sublingual tablets 100 mg: 50 pcs. |
Dosage Form, Packaging, and Composition
Sublingual tablets white, with a score line on one side and a bevel on two sides; marbling is allowed.
| 1 tab. | |
| Glycine | 100 mg |
Excipients: povidone (Kollidon 25) – 4 mg, magnesium stearate – 1 mg, microcrystalline cellulose – 5 mg.
50 pcs. – contour cell packs (1) – cardboard packs.
Buccal and sublingual tablets 100 mg: 25, 50, 100, or 150 pcs.
Marketing Authorization Holder
Tatkhimpharmpreparaty, JSC (Russia)
Dosage Form
|
Glycine | Buccal and sublingual tablets 100 mg: 25, 50, 100, or 150 pcs. |
Dosage Form, Packaging, and Composition
Buccal and sublingual tablets white, round, flat-cylindrical, with a bevel; slight marbling is allowed.
| 1 tab. | |
| Glycine | 100 mg |
Excipients: microcrystalline cellulose, povidone K-25 (medium molecular weight polyvinylpyrrolidone), magnesium stearate.
10 pcs. – contour cell packs (5) – cardboard packs.
25 pcs. – contour cell packs (1) – cardboard packs.
25 pcs. – contour cell packs (2) – cardboard packs.
25 pcs. – contour cell packs (4) – cardboard packs.
25 pcs. – contour cell packs (6) – cardboard packs.
Buccal and sublingual tablets 250 mg: 10, 20, 30, 50, 60, 90, 100, 150, 270, or 300 pcs.
Marketing Authorization Holder
Atoll LLC (Russia)
Manufactured By
Ozon, LLC (Russia)
Dosage Form
 |
Glycine forte | Buccal and sublingual tablets 250 mg: 10, 20, 30, 50, 60, 90, 100, 150, 270, or 300 pcs. |
Dosage Form, Packaging, and Composition
Buccal and sublingual tablets white or almost white, round, flat-cylindrical, with a cross-shaped score line on one side and bevels on two sides; slight marbling of the surface is allowed.
| 1 tab. | |
| Glycine | 250 mg |
Excipients: microcrystalline cellulose (MCC-101) – 80.65 mg, povidone K25 – 6.8 mg, magnesium stearate – 2.55 mg.
10 pcs. – cardboard contour cell packs – cardboard packs.
10 pcs. – cardboard contour cell packs (2) – cardboard packs.
10 pcs. – cardboard contour cell packs (3) – cardboard packs.
10 pcs. – cardboard contour cell packs (5) – cardboard packs.
10 pcs. – cardboard contour cell packs (9) – cardboard packs.
10 pcs. – cardboard contour cell packs (10) – cardboard packs.
30 pcs. – cardboard contour cell packs – cardboard packs.
30 pcs. – cardboard contour cell packs (2) – cardboard packs.
30 pcs. – cardboard contour cell packs (3) – cardboard packs.
30 pcs. – cardboard contour cell packs (5) – cardboard packs.
30 pcs. – cardboard contour cell packs (9) – cardboard packs.
30 pcs. – cardboard contour cell packs (10) – cardboard packs.
Buccal tablets 250 mg: 10, 20, 30, 50, 60, 90, or 100 pcs.
Marketing Authorization Holder
Canonpharma Production, CJS (Russia)
Dosage Form
|
Glycine Forte | Buccal tablets 250 mg: 10, 20, 30, 50, 60, 90, or 100 pcs. |
Dosage Form, Packaging, and Composition
| Buccal tablets | 1 tab. |
| Glycine | 250 mg |
10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (5) – cardboard packs.
10 pcs. – contour cell packs (6) – cardboard packs.
30 pcs. – contour cell packs (1) – cardboard packs.
30 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (9) – cardboard packs.
10 pcs. – contour cell packs (10) – cardboard packs.
30 pcs. – contour cell packs (3) – cardboard packs.
Sublingual tablets 250 mg: 10, 20, 25, 30, 50, 75, 90, 100, 125, 225, or 250 pcs.
Sublingual tablets 250 mg: 10, 20, 30, 50, 90, or 100 pcs.
Marketing Authorization Holder
Promomed Rus LLC (Russia)
Manufactured By
Ozon, LLC (Russia)
Or
Biokhimik, JSC (Russia)
Dosage Forms
|
Glycine Forte | Sublingual tablets 250 mg: 10, 20, 25, 30, 50, 75, 90, 100, 125, 225, or 250 pcs. |
| Sublingual tablets 250 mg: 10, 20, 30, 50, 90, or 100 pcs. |
Dosage Form, Packaging, and Composition
Sublingual tablets white or almost white, round, flat, with a cross-shaped score on one side and beveled edges on two sides; slight marbling is allowed.
| 1 tab. | |
| Glycine | 250 mg |
Excipients: microcrystalline cellulose (type 101) – 134 mg, povidone – 12 mg, magnesium stearate – 4 mg.
10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (5) – cardboard packs.
10 pcs. – contour cell packs (9) – cardboard packs.
10 pcs. – contour cell packs (10) – cardboard packs.
25 pcs. – contour cell packs (1) – cardboard packs.
25 pcs. – contour cell packs (2) – cardboard packs.
25 pcs. – contour cell packs (3) – cardboard packs.
25 pcs. – contour cell packs (5) – cardboard packs.
25 pcs. – contour cell packs (9) – cardboard packs.
25 pcs. – contour cell packs (10) – cardboard packs.
Sublingual tablets white or almost white, round, flat, with a cross-shaped score on one side and beveled edges on two sides; slight marbling is allowed.
| 1 tab. | |
| Glycine | 250 mg |
Excipients: microcrystalline cellulose (type 101) – 134 mg, povidone – 12 mg, magnesium stearate – 4 mg.
10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (5) – cardboard packs.
10 pcs. – contour cell packs (9) – cardboard packs.
10 pcs. – contour cell packs (10) – cardboard packs.
10 pcs. – glass jars (1) – cardboard packs.
20 pcs. – glass jars (1) – cardboard packs.
30 pcs. – glass jars (1) – cardboard packs.
50 pcs. – glass jars (1) – cardboard packs.
Sublingual tablets 50 mg: 10 or 50 pcs.
Marketing Authorization Holder
Ozon, LLC (Russia)
Dosage Form
|
Glycine Ozon | Sublingual tablets 50 mg: 10 or 50 pcs. |
Dosage Form, Packaging, and Composition
| Sublingual tablets | 1 tab. |
| Glycine | 50 mg |
10 pcs. – contour cell packs (1) – cardboard packs.
50 pcs. – contour cell packs (1) – cardboard packs.
Buccal and sublingual tablets 100 mg: 20, 28, 30, 50, 56, 60, 100, 105, 120 or 200
Marketing Authorization Holder
Obnovlenie Pfc, JSC (Russia)
Dosage Form
|
Glycine Renewal | Buccal and sublingual tablets 100 mg: 20, 28, 30, 50, 56, 60, 100, 105, 120 or 200 |
Dosage Form, Packaging, and Composition
Buccal and sublingual tablets white or almost white, round, flat-cylindrical, with a bevel; marbling may be present.
| 1 tab. | |
| Glycine | 100 mg |
Excipients: methylcellulose – 1 mg, magnesium stearate – 1 mg.
10 pcs. – cardboard cell packs (2) – cardboard packs.
10 pcs. – cardboard cell packs (3) – cardboard packs.
10 pcs. – cardboard cell packs (5) – cardboard packs.
10 pcs. – cardboard cell packs (10) – cardboard packs.
14 pcs. – cardboard cell packs (2) – cardboard packs.
14 pcs. – cardboard cell packs (4) – cardboard packs.
15 pcs. – cardboard cell packs (4) – cardboard packs.
15 pcs. – cardboard cell packs (7) – cardboard packs.
20 pcs. – cardboard cell packs (3) – cardboard packs.
20 pcs. – cardboard cell packs (6) – cardboard packs.
20 pcs. – cardboard cell packs (10) – cardboard packs.
Sublingual tablets 100 mg: 50 pcs.
Marketing Authorization Holder
Ozon, LLC (Russia)
Dosage Form
|
Glycine-Bio | Sublingual tablets 100 mg: 50 pcs. |
Dosage Form, Packaging, and Composition
Sublingual tablets white, with a score on one side and beveled edges on two sides; marbling may be present.
| 1 tab. | |
| Glycine | 100 mg |
Excipients: povidone (kollidon 25) – 4 mg, magnesium stearate – 1 mg, microcrystalline cellulose – 5 mg.
50 pcs. – contour cell packs (1) – cardboard packs.
Buccal tablets 1000 mg: 5, 10 or 20 pcs.
Marketing Authorization Holder
Canonpharma Production, CJS (Russia)
Dosage Form
|
Glycine-Canon | Buccal tablets 1000 mg: 5, 10 or 20 pcs. |
Dosage Form, Packaging, and Composition
| Buccal tablets | 1 tab. |
| Glycine | 1000 mg |
10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
5 pcs. – contour cell packs (1) – cardboard packs.
5 pcs. – contour cell packs (2) – cardboard packs.
5 pcs. – contour cell packs (4) – cardboard packs.
Sublingual tablets 100 mg: 50 pcs.
Marketing Authorization Holder
N.A. Semashko Moscow Chemical Pharmaceutical Preparations, JSC (Russia)
Dosage Form
|
Glycine-MHFP | Sublingual tablets 100 mg: 50 pcs. |
Dosage Form, Packaging, and Composition
Sublingual tablets white; marbling may be present.
| 1 tab. | |
| Glycine | 100 mg |
Excipients: methylcellulose (methylose) – 1.3 mg, magnesium stearate – 0.7 mg.
10 pcs. – contour cell packs (5) – cardboard packs.
![Glycine [Tablets] 1](https://www.medixlife.com/wp-content/uploads/Medixlife_favi_512.png "Glycine [Tablets] 2")